References
- 1. R. Fisher, W. Boas, W. Blume, C. Elger, P. Genton, P. Lee and J. Engel, Epileptic seizures and epilepsy: definitions proposed by the international league against epilepsy (ILAE) and the international bureau for epilepsy (IBE), Epilepsia46 (2005) 470–472; https://doi.org/10.1111/j.0013-9580.2005.66104.x
- 2. P. A. Dekker, Epilepsy: A Manual for Medical and Clinical Officers in Africa, WHO, Geneva 2002, pp. 133.
- 3. M. J. Brodie, A. T. Elder and P. Kwan, Epilepsy in later life, Lancet Neurol. 8 (2009) 1019–1030; https://doi.org/10.1016/S1474-4422(09)70240-6
- 4. E. Proulx, Y. Leshchenko, L. Kokarovtseva, V. Khokhotva, M. El-Beheiry, O. C. Snead and J. L. P. Velazquez, Functional contribution of specific brain areas to absence seizures: role of thalamic gapjunctional coupling, Eur. J. Neurosci.23 (2006) 489–496; https://doi.org/10.1111/j.1460-9568.2005.04558.x
- 5. S. F. Berkovic, R. A. Howell, D. A. Hay and J. L. Hopper, Epilepsies in twins: Genetics of the major epilepsy syndromes, Ann. Neurol.43 (1998) 435–445; https://doi.org/10.1002/ana.410430405
- 6. L. A. Corey, J. M. Pellock, M. J. Kjeldsen and K. O. Nakken, Importance of genetic factors in the occurrence of epilepsy syndrome type: A twin study, Epilepsy Res.97 (2011) 103–111; https://doi.org/10.1016/j.eplepsyres.2011.07.018
- 7. M. J. Kjeldsen, L. A. Corey, M. H. Solaas, M. L. Friis, J. R. Harris, K. O. Kyvik, K. Christensen and J. M. Pellock, Genetic factors in seizures: A population-based study of 47,626 US, Norwegian and Danish twin pairs, Twin Res. Hum. Genet.8 (2005) 138–147; https://doi.org/10.1375/1832427053738836
- 8. M. Li, X. Heng, R. Tao, J. Liu, L. Zhang, X. Sun, L. Wang, Q. Wu, F. Che and F. Xue, A genetic epidemiological survey of idiopathic epilepsy in the Chinese Han population, Epilepsy Res.98 (2012) 199–205; https://doi.org/10.1016/j.eplepsyres.2011.09.013
- 9. R. R. Nair and S. V. Thomas, Genetic liability to epilepsy in Kerala State India, Epilepsy Res.62 (2004) 163–170; https://doi.org/10.1016/j.eplepsyres.2004.08.007
- 10. R. Ottman, Genetic influences on risk for epilepsy, in Pediatric Epilepsy: Diagnosis and Therapy, Demos Medical Publishing, New York 2007.
- 11. H. J. Li, R. P. Wan, L. J. Tang, S. J. Liu, Q. H. Zhao, M. M. Gao, Y. H. Yi, W. P. Liao, X. F. Sun and Y. S. Long, Alteration of Scn3a expression is mediated via CpG methylation and MBD2 in mouse hippo-campus during postnatal development and seizure condition, Biochim. Biophys. Acta1849 (2015) 1–9; https://doi.org/10.1016/j.bbagrm.2014.11.004
- 12. K. Nagai, T. Natori, T. Nishino and F. Kodaira, Epigenetic dysregulation induces cell growth retardation in primary cultured glial cells, J. Biosci. Bioeng.105 (2008) 470–475; https://doi.org/10.1263/jbb.105.470
- 13. E. Hessen, M. I. Lossius, I. Reinvang and L. Gjerstad, Influence of major antiepileptic drugs on attention, reaction time, and speed of information processing: results from a randomized, double-blind, placebo-controlled withdrawal study of seizure-free epilepsy patients receiving monotherapy, Epilepsia47 (2006) 2038–2045; https://doi.org/10.1111/j.1528-1167.2006.00805.x
- 14. V. C. Terra, R. Amorim, C. Silvado, A. J. de Oliveira, C. L. Jorge, E. Faveret, P. Ragazzo and L. De Paola, Vagus nerve stimulator in patients with epilepsy: indications and recommendations for use, Arq. Neuro-Psiquiatr.71 (2013) 902–906; https://doi.org/10.1590/0004-282X20130116
- 15. P. Lisowska and B. Daly, Vagus nerve stimulation therapy (VNST) in epilepsy - implications for dental practice, Br. Dent. J.212 (2012) 69–72; https://doi.org/10.1038/sj.bdj.2012.47
- 16. B. M. Uthman, Vagus nerve stimulation for seizures, Arch. Med. Res.31 (2000) 300–303; https://doi.org/10.1016/S0188-4409(00)00060-6
- 17. I. S. Cooper and A. R. M. Upton, Use of chronic cerebellar stimulation for disorders of disinhibition, Lancet311 (1978) 595–600; https://doi.org/http://doi.org/10.1016/S0140-6736(78)91038-3
- 18. I. S. Cooper, A. R. M. Upton and I. Amin, Reversibility of chronic neurologic deficits: Some effects of electrical stimulation of the thalamus and internal capsule in man, Appl. Neurophysiol. 43 (1980) 224–258; https://doi.org/10.1159/000102263
- 19. K. W. Baranano and A. L. Hartman, The ketogenic diet: Uses in epilepsy and other neurologic illnesses, Curr. Treat. Options Neurol. 10 (2008) 410–419.
- 20. A. L. Rogovik and R. D. Goldman, Ketogenic diet for treatment of epilepsy, Can. Fam. Physician56 (2010) 540–542.
- 21. M. Greener, Food for thought: the ketogenic diet for epilepsy, Prog. Neurol. Psychiatry18 (2014) 6–9; https://doi.org/10.1002/pnp.329
- 22. M. Ne, L. Ngo, J. I. Sirven and M. R. Sperling, Ketogenic diet in adolescents and adults with epilepsy, Seizure23 (2014) 439–442; https://doi.org/10.1016/j.seizure.2014.02.015
- 23. R. Hanaya and K. Arita, The new antiepileptic drugs: their neuropharmacology and clinical indications, Neurol. Med. Chir. (Tokyo) 56 (2016) 205–220; https://doi.org/10.2176/nmc.ra.2015-0344
- 24. J. A. French and D. M. Gazzola, New generation antiepileptic drugs: what do they offer in terms of improved tolerability and safety? Ther. Adv. Drug Saf.2 (2011) 141–158; https://doi.org/10.1177/2042098611411127
- 25. G. Gatti, I. Bonomi, G. Jannuzzi and E. Perucca, The new antiepileptic drugs: Pharmacological and clinical aspects, Curr. Pharm. Design6 (2000) 839–860; https://doi.org/10.2174/1381612003400245
- 26. A. Nicolson and J. P. Leach, Future prospects for the drug treatment of epilepsy, CNS Drugs15 (2001) 955–968; https://doi.org/10.2165/00023210-200115120-00005
- 27. C. T. Supuran, F. Mincione, A. Scozzafava, F. Briganti, G. Mincione and M. A. Ilies, Carbonic anhydrase inhibitors – Part 52. Metal complexes of heterocyclic sulfonamides: A new class of strong topical intraocular pressure-lowering agents in rabbits, Eur. J. Med. Chem.33 (1998) 247–254; https://doi.org/10.1016/S0223-5234(98)80059-7
- 28. M. Ilies, C. T. Supuran, A. Scozzafava, A. Casini, F. Mincione, L. Menabuoni, M. T. Caproiu, M. Maganu and M. D. Banciu, Carbonic anhydrase inhibitors. Sulfonamides incorporating furan-, thiopheneand pyrrole-carboxamido groups possess strong topical intraocular pressure lowering properties as aqueous suspensions, Bioorg. Med. Chem. 8 (2000) 2145–2155; https://doi.org/10.1016/S0968-0896(00)00143-7
- 29. A. Scozzafava, L. Menabuoni, F. Mincone, F. Briganti, G. Mincione and C. T. Supuran, Carbonic anhydrase inhibitors. Perfluoroalkyl/aryl-substituted derivatives of aromatic/heterocyclic sulfonamides as topical intraocular pressure lowering agents with prolonged duration of action, J. Med. Chem.43 (2000) 4542–4551; https://doi.org/10.1021/jm000296j
- 30. A. Casini, A. Scozzafava, F. Mincione, L. Menabuoni, M. A. Ilies and C. T. Supuran, Carbonic anhydrase inhibitors: Water soluble 4-sulfamoylphenyl-thioureas as topical intraocular pressure-lowering agents with long-lasting effects, J. Med. Chem.43 (2000) 4884–4892; https://doi.org/10.1021/jm001051+
- 31. B. Masereel, S. Rolin, F. Abbate, A. Scozzafava and C. T. Supuran, Carbonic anhydrase inhibitors: Anticonvulsant sulfonamides incorporating valproyl and other lipophilic moieties, J. Med. Chem. 45 (2002) 312–320; https://doi.org/10.1021/jm0109199
- 32. M. A. Ilies, B. Masereel, S. Rolin, A. Scozzafava, G. Câmpeanu, V. Cîmpeanu and C. T. Supuran, Carbonic anhydrase inhibitors: aromatic and heterocyclic sulfonamides incorporating adamantyl moieties with strong anticonvulsant activity, Bioorg. Med. Chem.12 (2004) 2717–2726; https://doi.org/10.1016/j.bmc.2004.03.008
- 33. I. B. Linden, G. Gothoni, P. Kontro and S. S. Oja, Anticonvulsant activity of 2-phthalimidoethane sulphonamides: New derivatives of taurine, Neurochem. Int.5 (1983) 319–324; https://doi.org/10.1016/j.bmc.2004.03.008
- 34. O. Akgul, F. S. Kilic, K. Erol and V. Pabuccuoglu, Synthesis and anticonvulsant activity of some N-phenyl-2-phtalimidoethanesulfonamide derivatives, Arch. Pharm. (Weinheim) 340 (2007) 656–660; https://doi.org/10.1002/ardp.200700166
- 35. N. Siddiqui, M. F. Arshad, S. A. Khan and W. Ahsan, Sulfonamide derivatives of thiazolidin-4-ones with anticonvulsant activity against two seizure models: synthesis and pharmacological evaluation, J. Enzyme Inhib. Med. Chem.25 (2010) 485–491; https://doi.org/10.3109/14756360903282833
- 36. Y. Hu, C. Y. Li, X. M. Wang. Y. H. Yang and H. L. Zhu, 1,3,4-Thiadiazole: Synthesis, reactions, and applications in medicinal, agricultural, and materials chemistry, Chem. Rev.114 (2014) 5572–5610; https://doi.org/10.1021/cr400131u
- 37. A. K. Jain, S. Sharma, A. Vaidya, V. Ramachandran and R. K. Agrawal, 1,3,4-Thiadiazole and its derivatives: a review on recent progress in biological activities, Chem. Biol. Drug Des.81 (2013) 557–576; https://doi.org/10.1111/cbdd.12125
- 38. W. Dehaen, V. A. Bakulev, E. C. Taylor and J. A. Ellman, The Chemistry of 1,2,3-thiadiazoles, in The Chemistry of Heterocyclic Compounds (Ed. E. C. Taylor), 1st ed., John Wiley & Sons, New York 2004, pp. 5–240.
- 39. A. Gupta, P. Mishra, S. Kashaw, V. Jatav and J. P. Stables, Synthesis and anticonvulsant activity of some novel 3-arylamino/amino-4-aryl-5-imino-Δ2-1,2,4-thiadiazoline, Eur. J. Med. Chem.43 (2008) 749–754; https://doi.org/10.1016/j.ejmech.2007.05.008
- 40. A. Gupta, P. Mishra, S. N. Pandeya, S. K. Kashaw, V. Kashaw and J. P. Stables, Synthesis and anticonvulsant activity of some substituted 1,2,4-thiadiazoles, Eur. J. Med. Chem.44 (2009) 1100–1105; https://doi.org/10.1016/j.ejmech.2008.06.015
- 41. B. Ahamad and M. Yusuf, Synthesis of aromatic aldehyde imine derivative of 2-thiobenzyl-1,3,4-thiadiazole and evaluation of their anticonvulsant activity, Indian J. Chem. B 49 (2010) 241–246.
- 42. V. Jatav, P. Mishra, S. Kashaw and J. P. Stables, CNS depressant and anticonvulsant activities of some novel 3-[5-substituted1,3,4-thiadiazole-2-yl]-2-styryl quinazoline-4(3H)-ones, Eur. J. Med. Chem.43 (2008) 1945–1954; https://doi.org/10.1016/j.ejmech.2007.12.003
- 43. A. Foroumadi, V. Sheibani, A. Sakhteman, M. Rameshk, M. Abbasi, R. Farazifard, S. A. Tabatabai and A. Shafiee, Synthesis and anticonvulsant activity of novel 2-amino-5-[4-chloro-2-(2-chlorophenoxy) phenyl]-1,3,4-thiadiazole derivatives, DARU J. Pharm. Sci.15 (2007) 89–93.
- 44. X. Q. Deng, Z. Q. Dong, M. X. Song, B. Shu, S. B. Wang and Z. S. Quan, Synthesis and anticonvulsant activities of some triazolothiadiazole derivatives, Arch. Pharm. (Weinheim) 345 (2012) 565–573; https://doi.org/10.1002/ardp.201100326
- 45. H. Rajak, C. K. Behera, R. S. Pawar, P. K. Singour and M. D. Kharya, Synthesis and anticonvulsant evaluation of some novel 2,5-disubstituted 1,3,4-thiadiazoles: pharmacophore model studies, Acta Pol. Pharm.67 (2010) 503–510.
- 46. H. Rajak, B. S. Thakur, P. Kumar, P. Parmar, P. C. Sharma, R. Veerasamy and M. D. Kharya, Synthesis and antiepileptic activity of some novel semicarbazones containing 1,3,4-thiadiazole and quinazoline ring, Acta Pol. Pharm.69 (2012) 253–261.
- 47. N. Siddiqui, A. Rana, S. A. Khan, S. E. Haque, M. F. Arshad, S. Ahmed and W. Ahsan, Synthesis and preliminary screening of benzothiazol-2-yl-thiadiazole derivatives for anticonvulsant activity, Acta Pharm.59 (2009) 441–451; https://doi.org/10.2478/v10007-009-0031-x
- 48. M. S. Yar and M. W. Akhter, Synthesis and anticonvulsant activity of substituted oxadiazole and thiadiazole derivatives, Acta Pol. Pharm.66 (2009) 393–397.
- 49. K. P. Harish, K. N. Mohana and L. Mallesha, Synthesis of pyrazine substituted 1,3,4-thiadiazole derivatives and their anticonvulsant activity, Org. Chem. Int.2013 (2013) Article ID 631723 (8 pages); https://doi.org/10.1155/2013/631723
- 50. A. H. Al Rohaimi, Neuropharmacological and toxicity study of newly prepared N-[5-(3-chloro-4-fluorophenyl)-1,3,4-thiadiazol-2-yl]-2-substituted acetamides, Acta Pol. Pharm.72 (2015) 1315–1320.
- 51. J. R. Dimmock, S. C. Vashistha and J. P. Stable, Anticonvulsant properties of various acetylhydrazones, oxymoylhydrazones, and semicarbazones derived from aromatic and unsaturated carbonyl compounds, Eur. J. Med. Chem.35 (2000) 241–248; https://doi.org/10.1016/S0223-5234(00)00123-9
- 52. J. R. Dimmock, S. C. Vashistha and J. P. Stable, Ureylene anticonvulsants and related compounds, Pharmazie55 (2000) 490–494.
- 53. S. N. Pandeya, H. Manjula and J. P. Stables, Design of semicarbazones and their bio-isosteric analogues as potential anticonvulsants, Pharmazie56 (2001) 121–124.
- 54. S. N. Pandeya, I. Ponnilavarasan, A. Pandey, R. Lakhan and J. P. Stables, Evaluation of p-nitrophenyl substituted semicarbazones for anticonvulsant properties, Pharmazie54 (1999) 923–925.
- 55. J. R. Dimmock, R. N. Puthucode, J. Tuchek, J. B. Baker, C. N. Hinko, C. L. Steinmiller and J. P. Stable, Anticonvulsant activity of 4-(4’-fluorophenoxy)benzaldehyde semicabazone, Drug. Dev. Res.46 (1999) 112–125; https://doi.org/10.1002/(SICI)1098-2299(199902)46:2<112::AID-DDR4>3.0.CO;2-N
- 56. O. Alam, P. Mallick, S. P. Verma, S. J. Gilani, S. A. Khan, N. Siddiqui and W. Ahsan, Synthesis, anticonvulsant and toxicity screening of newer pyrimidine semicarbazone derivatives, Eur. J. Med. Chem.45 (2010) 2467–2472; https://doi.org/10.1016/j.ejmech.2010.02.031
- 57. P. Yogeeswari, D. Sriram, S. Mehta, D. Nigam, M. M. Kumar, S. Murugesan and J. P. Stables, Anticonvulsant and neurotoxicity evaluation of some 6-substituted benzothiazolyl-2-thiosemicarbazones, I. L. Farmaco60 (2005) 1–5; https://doi.org/10.1016/j.farmac.2004.09.001
- 58. P. Yogeeswari, D. Sriram, V. Saraswat, J. V. Ragavendran, M. M. Kumar, S. Murugesan, R. Thirumurugan and J. P. Stables, Synthesis and anticonvulsant and neurotoxicity evaluation of N4-phthalimido phenyl (thio) semicarbazides, Eur. J. Pharm. Sci.20 (2003) 341–346; https://doi.org/10.1016/j.ejps.2003.08.002
- 59. U. Çalış, E. Septioğlu and M. D. Aytemir, Synthesis and anticonvulsant evaluation of some novel (thio) semicarbazone derivatives of arylalkylimidazole, Arzneimittelforschung61 (2011) 327–334; https://doi.org/10.1055/s-0031-1296206
- 60. F. Azam, I. A. Alkskas, S. L. Khokra and O. Prakash, Synthesis of some novel N4-(naphtha[1,2-d]thiazol-2-yl)semicarbazone as potential anticonvulsants, Eur. J. Med. Chem.44 (2009) 203–209; https://doi.org/10.1016/j.ejmech.2008.02.007
- 61. E. D. Ilieva, N. I. Petkova and R. D. Nikolova, A new and efficient method for the synthesis of 3,4-di-substituted pyrrolidine-2,5-diones, Molecules17 (2012) 4936–4949; https://doi.org/10.3390/molecules17054936
- 62. J. Obniska and K. Kamiński, Synthesis and anticonvulsant properties of new N-phenylamino derivatives of 2-azaspiro[4.4]nonane, 2-azaspiro[4.5]decane-1,3-dione and 3 cyclohexyl-pyrrolidine-2,5-dione. Part IV, Acta Pol. Pharm.63 (2006) 101–108.
- 63. J. Obniska and K. Kamiński, Lipophilicity characterization of new N-phenylamino-azaspiranes as potential anticonvulsant agents, Biomed. Chromatogr. 20 (2006) 1185–1191; https://doi.org/10.1002/bmc.682
- 64. J. Obniska, R. Lesyk, D. Atamanyuk and K. Kamiński, Synthesis and anticonvulsant activity of a series of N-substituted bicyclo[2,2,1]hept-5-ene-2,3-dicarboximides, Acta Pol. Pharm.62 (2005) 213–219.
- 65. J. Obniska, S. Jurczyk, A. Zejc, K. Kamiński, E. Tatarczynska and K. Stachowicz, Anticonvulsant properties of N-(4-methylpiperazin-1-yl)- and N-[3-(4-methylpiperazin-1-yl)propyl] derivatives of 3-aryl and 3-spirocycloalkyl-pyrrolidine-2,5-dione, Pharmacol. Rep.57 (2005) 170–175.
- 66. K. Kamiński and J. Obniska, Design, synthesis, and anticonvulsant activity of N-phenylamino derivatives of 3,3-dialkyl-pyrrolidine-2,5-diones and hexahydro-isoindole-1,3-diones, Bioorg. Med. Chem.16 (2008) 4921–4931; https://doi.org/10.1016/j.bmc.2008.03.037
- 67. J. Obniska, K. Kamiński, D. Skrzynska and J. Pichor, Synthesis and anticonvulsant activity of new N-[(4-arylpiperazin-1-yl)-alkyl] derivatives of 3-phenyl-pyrrolidine-2,5-dione, Eur. J. Med. Chem.44 (2009) 2224–2233; https://doi.org/10.1016/j.ejmech.2008.05.020
- 68. J. Obniska, M. Kopytko, A. Zagórska, I. Chlebek and K. Kamiński, Synthesis and anticonvulsant properties of new Mannich bases derived from 3-aryl-pyrrolidine-2,5-diones. Part 1, Arch. Pharm. (Weinheim) 343 (2010) 333–341; https://doi.org/10.1002/ardp.200900250
- 69. K. Kamiński, S. Rzepka and J. Obniska, Synthesis and anticonvulsant activity of new 1-[2-oxo-2-(4-phenylpiperazin-1-yl)ethyl]pyrrolidine-2,5-diones, Bioorg. Med. Chem. Lett.21 (2011) 5800–803; https://doi.org/10.1016/j.bmcl.2011.07.118
- 70. J. Obniska, I. Chlebek and K. Kamiński, Synthesis and anticonvulsant properties of new Mannich bases derived from 3,3-disubstituted pyrrolidine-2,5-diones, Part IV, Arch. Pharm. (Weinheim) 345 (2012) 713–722; https://doi.org/10.1002/ardp.201200092
- 71. K. Kamiński, J. Obniska, I. Chlebek, B. Wiklik and S. Rzepka, Design, synthesis and anticonvulsant properties of new N-Mannich bases derived from 3-phenylpyrrolidine-2,5-diones, Bioorg. Med. Chem. Lett.21 (2013) 6821–6830; https://doi.org/10.1016/j.bmc.2013.07.029
- 72. J. Obniska, I. Chlebek, K. Kamiński and J. Karolak-Wojciechowska, Synthesis and anticonvulsant properties of new N-Mannich bases derived from 3, 3-diphenyl- and 3-ethyl-3-methyl-pyrrolidine-2,5-diones, Part III, Arch. Pharm. (Weinheim) 346 (2013) 71–82; https://doi.org/10.1002/ardp.201200265
- 73. K. Kamiński, B. Wiklik and J. Obniska, Synthesis, anticonvulsant properties, and SAR analysis of differently substituted pyrrolidine-2,5-diones and piperidine-2,6-diones, Arch. Pharm. (Weinheim) 347 (2014) 840–852; https://doi.org/10.1002/ardp.201400179
- 74. S. Rybka, J. Obniska, A. Rapacz, B. Filipek and K. Kamiński, Synthesis, physicochemical, and anticonvulsant properties of new N-Mannich bases derived from pyrrolidine-2,5-dione and its 3-methyl analog, Arch. Pharm. (Weinheim) 347 (2014) 768–776; https://doi.org/10.1002/ardp.201400152
- 75. J. Obniska, A. Rapacz, S. Rybka, B. Powroznik, E. Pekala, B. Filipek, P. Zmudzki and K. Kamiński, Design, synthesis and biological activity of new amides derived from 3-methyl-3-phenyl-2, 5-dioxopyrrolidin-1-yl-acetic acid, Eur. J. Med. Chem.102 (2015) 14–25; https://doi.org/10.1016/j.ejmech.2015.07.017
- 76. K. Kamiński, M. Zagaja, A. Rapacz, J. J. Tuszczki, M. Andres-Mach, M. Abram and J. Obniska, New hybrid molecules with anticonvulsant and antinociceptive activity derived from 3-methyl- or 3,3-dimethyl-1-[1-oxo-1-(4-phenylpiperazin-1-yl) propan-2-yl]pyrrolidine-2,5-diones, Bioorg. Med. Chem.24 (2016) 606–618; https://doi.org/10.1016/j.bmc.2015.12.027
- 77. A. Rapacz, S. Rybka, J. Obniska, K. Sałat, B. Powroźnik, E. Pękala and B. Filipek, Evaluation of anticonvulsant and antinociceptive properties of new N-Mannich bases derived from pyrrolidine-2,5-dione and 3-methylpyrrolidine-2,5-dione, Naunyn-Schmiedeberg Arch. Pharmacol.389 (2016) 339–348; https://doi.org/10.1007/s00210-015-1194-2
- 78. S. Rybka, J. Obniska, A. Rapacz, B. Filipek and P. Zmudzki, Synthesis and anticonvulsant activity of new N-Mannich bases derived from benzhydryl- and isopropyl-pyrrolidine-2,5-dione, J. Enzyme Inhib. Med. Chem.31 (2016) 1038–1047; https://doi.org/10.3109/14756366.2015.1088842
- 79. S. Rybka, J. Obniska, A. Rapacz, B. Filipek and P. Zmudzki, Synthesis and evaluation of anticonvulsant properties of new N-Mannich bases derived from pyrrolidine-2,5-dione and its 3-methyl-, 3-isopropyl, and 3-benzhydryl analogs, Bioorg. Med. Chem. Lett.27 (2017) 1412–1415; https://doi.org/10.1016/j.bmcl.2017.02.002
- 80. F. Schiaffella, A. Macchiarulo, L. Milanese, A. Vecchiarelli and R. Fringuelli, Novel ketoconazole analogues based on the replacement of 2,4-dichlorophenyl group with 1,4-benzothiazine moiety: Design, synthesis, and microbiological evaluation, Bioorg. Med. Chem.14 (2006) 5196–5203; https://doi.org/10.1016/j.bmc.2006.04.004
- 81. L. Navidpour, H. Shadnia, H. Shafaroodi, M. Amini, A. R. Dehpour and A. Shafiee, Design, synthesis, and biological evaluation of substituted 2-alkylthio-1,5-diarylimidazoles as selective COX-2 inhibitors, Bioorg. Med. Chem.15 (2007) 1976–1982; https://doi.org/10.1016/j.bmc.2006.12.041
- 82. J. C. Thenmozhiyal, P. T. Wong and W. K. Chui, Anticonvulsant activity of phenylmethyl-enehydantoins: A structure-activity relationship study, J. Med. Chem.47 (2004) 1527–1535; https://doi.org/10.1021/jm030450c
- 83. A. Karakurt, M. Ozalp, S. Isik, J. P. Stables and S. Dalkara, Synthesis, anticonvulsant and antimicrobial activities of some new 2-acetylnaphthalene derivatives, Bioorg. Med. Chem.18 (2010) 2902–2911; https://doi.org/10.1016/j.bmc.2010.03.010
- 84. A. Husain, N. Siddiqui, M. Sarafroz, Y. Khatoon, M. Rasid and N. Ahmad, Synthesis, anticonvulsant and neurotoxicity screening of some novel 1,2,4-trisubstituted-1H-imidazole derivatives, Acta Pol. Pharm.68 (2011) 657–663.
- 85. M. Amir, I. Ali and M. Z. Hassan, Imidazole incorporated semicarbazone derivatives as a new class of anticonvulsants: Design, synthesis and in vivo screening, Med. Chem.9 (2013) 571–580; https://doi.org/10.2174/1573406411309040011
- 86. S. Ulloora, R. Shabaraya, S. Aamir and A. V. Adhikari, New imidazo[1,2-a]pyridines carrying active pharmacophores: Synthesis and anticonvulsant studies, Bioorg. Med. Chem. Lett.23 (2013) 1502–1506; https://doi.org/10.1016/j.bmcl.2012.12.035
- 87. S. Ulloora, R. Shabaraya and A. V. Adhikari, Facile synthesis of new imidazo[1,2-a] pyridines carrying 1,2,3-triazoles via click chemistry and their antiepileptic studies, Bioorg. Med. Chem. Lett.23 (2013) 3368–3372; https://doi.org/10.1016/j.bmcl.2013.03.086
- 88. M. I. Attia, M. N. Aboul-Enein, A. A. El-Azzouny, Y. A. Maklad and H. A. Ghabbour, Anticonvulsant potential of certain new (2E)-2-[1-aryl-3-(1H-imidazol-1-yl)propylidene]-N-(aryl/H) hydrazinecarboxamides, Sci. World J. 2014 (2014) Article ID 357403 (9 pages); https://doi.org/10.1155/2014/357403
- 89. R. K. Gill, R. K. Rawal and J. Bariwal, Recent advances in the chemistry and biology of benzothiazoles, Arch. Pharm. (Weinheim) 348 (2015) 155–178; https://doi.org/10.1002/ardp.201400340
- 90. N. Siddiqui, A. Rana, S. A. Khan, M. A. Bhat and S. E. Haque, Synthesis of benzothiazole semicarbazones as novel anticonvulsants - the role of hydrophobic domain, Bioorg. Med. Chem. Lett.17 (2007) 4178–4182; https://doi.org/10.1016/j.bmcl.2007.05.048
- 91. A. Rana, N. Siddiqui, S. A. Khan, S. E. Haque and M. A. Bhat, N-{[(6-substituted-1,3-benzothiazole-2-yl)amino]carbonothioyl}-2/4-substituted benzamides: Synthesis and pharmacological evaluation, Eur. J. Med. Chem.43 (2008) 1114–1122; https://doi.org/10.1016/j.ejmech.2007.07.008
- 92. M. Z. Hassan, S. A. Khan and M. Amir, Design, synthesis and evaluation of N-(substituted benzothiazol-2-yl) amides as anticonvulsant and neuroprotective, Eur. J. Med. Chem.58 (2012) 206–213; https://doi.org/10.1016/j.ejmech.2012.10.002
- 93. N. Siddiqui, A. Rana, S. A. Khan, S. E. Haque, M. F. Arshad, S. Ahmed and W. Ahsan, Synthesis and preliminary screening of benzothiazol-2-yl thiadiazole derivatives for anticonvulsant activity, Acta Pharm. 59 (2009) 441–451; https://doi.org/10.2478/v10007-009-0031-x
- 94. N. Siddiqui, S. N. Pandeya, S. A. Khan, J. Stables, A. Rana, M. Alam, M. F. Arshad and M. A. Bhat, Synthesis and anticonvulsant activity of sulfonamide derivatives-hydrophobic domain, Bioorg. Med. Chem. Lett.17 (2007) 255–259; https://doi.org/10.1016/j.bmcl.2006.09.053
- 95. A. A. Farag, S. N. Abd-Alrahman, G. F. Ahmed, R. M. Ammar, Y. A. Ammar and S. Y. Abbas, Synthesis of some azoles incorporating a sulfonamide moiety as anticonvulsant agents, Arch. Pharm. (Weinheim) 345 (2012) 703–712; https://doi.org/10.1002/ardp.201200014
- 96. N. Siddiqui, M. F. Arshad and S. A. Khan, Synthesis of some new coumarin incorporated thiazolyl semicarbazones as anticonvulsants, Acta Pol. Pharm. 66 (2009) 161–167.
- 97. D. C. Liu, X. Q. Deng, S. B. Wang and Z. S. Quan, Synthesis and anticonvulsant activity evaluation of 7-alkoxy[1,2,4]triazolo[3,4-b]benzothiazol-3(2H)-ones, Arch. Pharm. (Weinheim) 347 (2014) 268–275; https://doi.org/10.1002/ardp.201300277
- 98. X. Q. Deng, M. X. Song, C. X. Wei, F. N. Li and Z. S. Quan, Synthesis and anticonvulsant activity of 7-alkoxy-triazolo-[3,4-b]benzo[d]thiazoles, Med. Chem.6 (2010) 313–320; https://doi.org/10.2174/157340610793358855
- 99. N. Siddiqui, A. Rana, S. A. Khan, S. E. Haque, M. S. Alam, W. Ahsan and S. Ahmed, Synthesis of 8-substituted-4-(2/4-substituted phenyl)-2H-[1,3,5]triazino[2,1-b][1,3]benzothiazole-2-thiones and their anticonvulsant, anti-nociceptive, and toxicity evaluation in mice, J. Enzyme Inhib. Med. Chem.24 (2009) 1344–1350; https://doi.org/10.3109/14756360902888176
- 100. D. Liu, H. Zhang, C. Jin and Z. Quan, Synthesis and biological evaluation of novel benzothiazole derivatives as potential anticonvulsant agents, Molecules21 (2016) Article ID 164 (13 pages); https://doi.org/10.3390/molecules21030164
- 101. J. D. Conley and H. Kohn, Functionalized DL-amino acid derivatives. Potent new agents for the treatment of epilepsy, J. Med. Chem.30 (1987) 567–574; https://doi.org/10.1021/jm00386a021
- 102. H. Kohn, J. D. Conley and J. D. Leander, Marked stereospecificity in a new class of anticonvulsants, Brain Res.457 (1988) 371–375; https://doi.org/10.1016/0006-8993(88)90709-3
- 103. H. Kohn, K. N. Sawhney, P. LeGall, J. D. Conley, D. W. Robertson and J. D. Leander, Preparation and anticonvulsant activity of a series of functionalized α-aromatic and α-heteroaromatic amino acids, J. Med. Chem.33 (1990) 919–926; https://doi.org/10.1021/jm00165a006
- 104. H. Kohn, K. N. Sawhney, P. LeGall, D. W. Robertson and J. D. Leander, Preparation and anticonvulsant activity of a series of functionalized α-heteroatom-substituted amino acids, J. Med. Chem.34 (1991) 2444–2452; https://doi.org/10.1021/jm00112a020
- 105. H. Kohn, K. N. Sawhney, P. Bardel, D. W. Robertson and J. D. Leander, Synthesis and anticonvulsant activities of α-heterocyclic α-acetamido-N-benzylacetamide derivatives, J. Med. Chem.36 (1993) 3350–3360; https://doi.org/10.1021/jm00074a016
- 106. K. E. Andersen, C. Braestrup, F. C. Groenwald, A. S. Joergensen, E. B. Nielsen, U. Sonnewald, P. O. Soerensen, P. D. Suzdak and L. J. S. Knutsen, The synthesis of novel GABA uptake inhibitors. 1. Elucidation of the structure-activity studies leading to the choice of (R)-1-[4,4-bis(3-methyl-2-thienyl)-3-butenyl]-3-piperidinecarboxylic acid (Tiagabine) as an anticonvulsant drug candidate, J. Med. Chem.36 (1993) 1716–1725; https://doi.org/10.1021/jm00064a005
- 107. J. Zheng, R. Wen, X. Luo, G. Lin, J. Zhang, L. Xu, L. Guo and H. Jiang, Design, synthesis, and biological evaluation of the N-diarylalkenyl-piperidinecarboxylic acid derivatives as GABA uptake inhibitors (I), Bioorg. Med. Chem. Lett.16 (2006) 225–227; https://doi.org/10.1016/j.bmcl.2005.09.004
- 108. N. Yadav, M. Malhotra, V. Monga, S. Sharma, J. Jain, Abdul Samad and A. Deep, Synthesis, characterization, and pharmacological evaluation of new GABA analogs as potent anticonvulsant agents, Med. Chem. Res.21 (2012) 2208–2216; https://doi.org/10.1007/s00044-011-9743-9
- 109. R. Torregrosa, X. F. Yang, E. T. Dustrude, T. R. Cummins, R. Khanna and H. Kohn, Chimeric derivatives of functionalized amino acids and α-aminoamides: Compounds with anticonvulsant activity in seizure models and inhibitory actions on central, peripheral, and cardiac isoforms of voltage-gated sodium channels, Bioorg. Med. Chem.23 (2015) 3655–3666; https://doi.org/10.1016/j.bmc.2015.04.014
- 110. C. O. Usifoh, D. M. Lambert, J. Wouters and G. K. E. Scriba, Synthesis and anticonvulsant activity of N,N-phthaloyl derivatives of central nervous system inhibitory amino acids, Arch. Pharm. (Weinheim) 334 (2001) 323–331; https://doi.org/10.1002/1521-4184(200110)334:10<323::AIDARDP323>3.0.CO;2-O